Aptevo Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 5, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 5, 2024

APVO$1.13-8.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. Form 10-K Summary

We have chosen not to include the summary permitted by this Item 16.

SIGNAT URES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Aptevo Therapeutics Inc.
Date: March 5, 2024	By:	/s/ Marvin L. White
		Marvin L. White
		President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

John E. Niederhuber, M.D.
Name	Title	Date
/s/Marvin L. White	President, Chief Executive Officer and Director	March 5, 2024
Marvin L. White	(Principal Executive Officer)
/s/Daphne Taylor	Senior Vice President and Chief Financial Officer	March 5, 2024
Daphne Taylor	(Principal Financial and Accounting Officer)
/s/John E. Niederhuber, M.D.	Chairman of the Board of Directors	March 5, 2024
/s/Daniel J. Abdun-Nabi	Director	March 5, 2024
Daniel J. Abdun-Nabi
/s/Grady Grant, III	Director	March 5, 2024
Grady Grant, III
/s/Zsolt Harsanyi, Ph. D.	Director	March 5, 2024
Zsolt Harsanyi, Ph. D.
/s/Barbara Lopez Kunz	Director	March 5, 2024
Barbara Lopez Kunz

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.